Optical phase conjugation (OPC) has emerged as a powerful technique to counteract the deleterious effects of nonlinearity and dispersion in fibre communication systems. By generating a phase-inverted ...

The 21-valent pneumococcal conjugate vaccine candidate, GBP410 (also known as SP0202), demonstrates positive safety and immunogenicity data from the Phase II study. SK bioscience and Sanofi plan to ...

Vaxcyte Inc. (NASDAQ:PCVX) on Monday released topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate ...

Pneumococcal disease remains a major global health challenge despite the availability of current vaccines This 21-valent pneumococcal conjugate vaccine (PCV21) is the first pneumococcal conjugate ...

Merck's (NYSE:MRK) experimental antibody drug conjugate zilovertamab vedotin, in combination with standard of care, demonstrated encouraging antitumor activity in the phase 2 portion of a study of ...

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the first patient was dosed in its Phase 1 study ...